You searched for "infections"
RTP801 as a neuroprotective and axon regenerative treatment
This paper describes the neuroprotective and axon regenerative effects of siRTP801, which is a translatable small-interfering RNA (siRNA) targeting mTOR negative regulator; RTP801, through in-vivo and in-vitro models. In-vivo studies involved an optic nerve crush rat model with intravitreal injections...
Combined anti-VEGF and PDT for wet AMD
The authors report on a retrospective case series of combined anti-VEGF and photodynamic therapy (PDT) in the treatment of wet age-related macular degeneration (AMD) refractory to anti-VEGF monotherapy alone. The criteria for treatment failure of anti-VEGF monotherapy were persistent subretinal...
Subthreshold micropulse laser in BRVO
The purpose of this retrospective, consecutive, single-centre, non-randomised, and case-control study was to verify the therapeutic effects and safety of oedema (from branch retinal vein occlusion (BRVO)) recurrence suppression effect using 577-nm subthreshold micropulse laser photocoagulation (SMLP) in combination with...
RPE tears in cases of IPCV
The aim of this study was to investigate the occurrence, characteristics, management and prognosis of retinal pigment epithelium (RPE) tears in patients with polypoidal choroidal vasculopathy (PCV). Medical records of previous cases were reviewed over an eight-year period from a...
Comparing bimedial rectus recession and botulinum toxin for partially accommodative esotropia
The authors present a retrospective case review to compare bimedial rectus recession and botulinum toxin injection to the medial recti. This study was possible due to the different first-line preferences of the individual surgeons within the team. Inclusion criteria were...
Aflibercept, bevacizumab or ranibizumab for DMO
This is a two-year randomised clinical trial of 660 patients with visual acuity impairment from diabetic macular oedema (DMO) who were randomised to monthly injections of 2.0mg aflibercept, 1.25 mg bevacizumab or 0.3mg ranibizumab. Focal or grid laser was performed...
Two-year results of a T&E aflibercept regime in caucasian PNV
This a retrospective study examining two-year outcomes of patients with pachychoroid neovasculopathy (PNV) treated with a treat and extend (T&E) regimen of intravitreal aflibercept. The mean age was 63.84 ± 7.92 years with nine males (35%) and 17 females (65%)....Macular imagery: observing the visual sensations pre- and post-Jetrea injections
A 63-year-old woman, a professional painter, was diagnosed with vitreomacular traction (VMT) in 2017. She had a history of metamorphopsia, drop in visual acuity (VA) in the left eye (6/6 in the RE; 6/18 in the LE), foveal vitreomacular traction...Lessons from an unusual case of syphilis
The rise of syphilis transmission rates over the past two decades has been one of public health’s great puzzles. In the UK, the situation has reached epidemic levels, with a 126% increase between 2013 and 2018 [1]. We present a...Initiatives in macular service provision
A report from Monitor in October 2015 identifies good practices that will realise most of the potential productivity gain in elective care available to NHS hospitals. These include: stratifying patients by risk and creating low-complexity pathways for lower-risk patients (tailoring...
Does paediatric uveitis reactivate after treatment with anti-TNF-a drugs?
As a potentially blinding disease that can affect 7-27/100000 children, uveitis remains a rare condition, where little evidence based data is available to guide management decisions. Most paediatric uveitis cases are chronic, anterior and non-infectious and may be associated with...
